Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

@article{Giacomo2012IpilimumabAF,
  title={Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.},
  author={Anna Maria Di Giacomo and Paolo Antonio Ascierto and Lorenzo Pilla and Mario Santinami and Pier Francesco Ferrucci and Diana Giannarelli and Antonella Marasco and Licia Rivoltini and Ester Simeone and Stefania V L Nicoletti and Ester Fonsatti and Diego Annesi and P. J. Queirolo and Alessandro Testori and Ruggero Ridolfi and Giorgio Parmiani and Michele Maio},
  journal={The Lancet. Oncology},
  year={2012},
  volume={13 9},
  pages={879-86}
}
BACKGROUND Ipilimumab improves survival of patients with metastatic melanoma, many of whom develop brain metastases. Chemotherapy-induced release of tumour antigens might amplify ipilimumab's antitumour activity. We aimed to investigate the efficacy and safety of ipilimumab plus fotemustine in patients with metastatic melanoma with or without asymptomatic brain metastases. METHODS In our open-label, single-arm phase 2 trial, we enrolled patients 18 years or older with measurable, locally… CONTINUE READING